Integrin αIIbβ3 specific antibodies and peptides

Abstract

The present invention provides integrin α IIb β 3 specific antibodies and peptides. The antibodies and peptides demonstrate little or no immunoreactivity with other integrins. Methods for inhibiting platelet aggregation using the antibodies and peptides are also provided.

What is claimed is: 
     
       1. An antibody that binds integrin α II β 3  and comprises a heavy chain variable region sequence selected from the group consisting of SEQ ID Nos:32, 33, 37 and 38. 
     
     
       2. The antibody of  claim 1 , wherein the antibody has a dissociation constant (K d ) from between 10 −8  M and 10 −11  M. 
     
     
       3. The antibody of  claim 1  that is a human antibody. 
     
     
       4. A pharmaceutical composition comprising the antibody of  claim 1  and a suitable pharmaceutical carrier in a form suitable for administration intravenously, intra-arterially, into the lymphatic circulation, intraperitoneally, transdermally, subcutaneously, intramuscularly, into the joint space, or by pulmonary administration. 
     
     
       5. An antibody as claimed in  claim 1  for use as a medicament for treatment to prevent thrombosis in conditions selected from the group consisting of pulmonary embolism, transient ischemic attacks (TIAs), deep vein thrombosis, coronary bypass surgery, and surgery to insert a prosthetic valve or vessel in autologous, non-autologous or synthetic vessel graft. 
     
     
       6. An antibody as claimed in  claim 1  for use as a medicament for treatment to prevent thrombosis in procedure selected from the group consisting of angioplasty procedures performed by balloon, coronary atherectomy, and laser angioplasty. 
     
     
       7. A method of inhibiting platelet aggregation comprising contacting platelets with an effective inhibitory amount of the antibody of  claim 1 . 
     
     
       8. A method of inhibiting binding of fibrinogen to platelets comprising contacting platelets with an effective inhibitory amount of the antibody of  claim 1 . 
     
     
       9. A method of treating a subject to treat a disorder of thrombus formation, the disorder selected from the group consisting of thrombosis in pulmonary embolism, transient ischemic attacks (TIAs), deep vein thrombosis, coronary bypass surgery, surgery to insert a prosthetic valve or vessel in autologous, non-autologous, or synthetic vessel graft the method comprising administering to the subject an amount of an antibody as claimed in  claim 1  effective to achieve the desired treatment. 
     
     
       10. A method of treating a subject to treat a disorder of thrombus formation, the disorder selected from the group consisting of thrombosis in pulmonary embolism, transient ischemic attacks (TIAs), deep vein thrombosis, coronary bypass surgery, surgery to insert a prosthetic valve or vessel in autologous, non-autologous, or synthetic vessel graft, the method comprising administering to the subject an amount of a pharmaceutical composition as claimed in  claim 4  effective to achieve the desired treatment.